NEW YORK (GenomeWeb News) — SIRS-Lab has adopted an Illumina gene-expression system for its expression services, and has stopped using the internally developed gene-expression system it had offered over the past five years, according to a company scientist.
“Before we were making our own arrays, but we decided to stop this business,” SIRS-Lab’s Julien Landre told GenomeWeb Daily News sister publication BioArray News this week. “The Illumina platform is new. We’ve been in this business for quite awhile, and when it comes to gene expression, this platform suits us best.”
Customers for Jena, Germany-based SIRS-Lab’s gene-expression service include the William Harvey Research Institute in London and Charité University in Berlin, according to a statement from the company.
SIRS-Lab currently has a separate diagnostic-discovery program focusing on sepsis, but Landre said that the company has not made a decision on what platform it will use for future tests.
This article originally appeared in the current issue of BioArray News, a GenomeWeb Daily News sister publication.